Refine
Year of publication
Language
- English (1032)
Has Fulltext
- yes (1032)
Is part of the Bibliography
- no (1032)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- pp collisions (3)
- Beauty production (2)
- Charm physics (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Single electrons (2)
- 900 GeV (1)
- AA-amylodosis (1)
- ALICE detector (1)
- Adolescence (1)
- Anti-nuclei (1)
- Assessment (1)
- Boosted Jets (1)
- Centrality Class (1)
- Centrality Selection (1)
- Chronic kidney disease (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Data sharing (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- HBT (1)
- HIV (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- IVDU (1)
- Identity (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- Material budget (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Neural network (1)
- Nuclear modification factor (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Personality disorder (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton–proton (1)
- Psychopathology (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Single muons (1)
- Systematic Uncertainty (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- acute kidney injury (1)
- arterial hypertension (1)
- baroreflex (1)
- complications (1)
- dE/dx (1)
- detector (1)
- experimental results (1)
- global change (1)
- habitat destruction (1)
- heavy ion experiments (1)
- irbesartan (1)
- land use (1)
- neurocritical care (1)
- outcome (1)
- quark gluon plasma (1)
- spectra (1)
- sympathetic nervous system (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1025)
- Frankfurt Institute for Advanced Studies (FIAS) (955)
- Informatik (921)
- Medizin (6)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
- Biodiversität und Klima Forschungszentrum (BiK-F) (1)
- Institut für Ökologie, Evolution und Diversität (1)
- Pharmazie (1)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (1)
Epoxyeicotrienoic acids (EETs) are cytochrome P450-dependent anti-hypertensive and anti-inflammatory derivatives of arachidonic acid, which are highly abundant in the kidney and considered reno-protective. EETs are degraded by the enzyme soluble epoxide hydrolase (sEH) and sEH inhibitors are considered treatment for chronic renal failure (CRF). We determined whether sEH inhibition attenuates the progression of CRF in the 5/6-nephrectomy model (5/6-Nx) in mice. 5/6-Nx mice were treated with a placebo, an ACE-inhibitor (Ramipril, 40 mg/kg), the sEH-inhibitor cAUCB or the CYP-inhibitor fenbendazole for 8 weeks. 5/6-Nx induced hypertension, albuminuria, glomerulosclerosis and tubulo-interstitial damage and these effects were attenuated by Ramipril. In contrast, cAUCB failed to lower the blood pressure and albuminuria was more severe as compared to placebo. Plasma EET-levels were doubled in 5/6 Nx-mice as compared to sham mice receiving placebo. Renal sEH expression was attenuated in 5/6-Nx mice but cAUCB in these animals still further increased the EET-level. cAUCB also increased 5-HETE and 15-HETE, which derive from peroxidation or lipoxygenases. Similar to cAUCB, CYP450 inhibition increased HETEs and promoted albuminuria. Thus, sEH-inhibition failed to elicit protective effects in the 5/6-Nx model and showed a tendency to aggravate the disease. These effects might be consequence of a shift of arachidonic acid metabolism into the lipoxygenase pathway.
Background: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Methods: Retrospective investigation including all patients with prior or present IVDU that underwent renal biopsy because of chronic kidney disease between 01.04.2002 and 31.03.2012 in the city of Frankfurt/Main, Germany.
Results: Twenty four patients with IVDU underwent renal biopsy because of progressive chronic kidney disease or proteinuria. Renal AA-amyloidosis was the predominant cause of renal failure in 50% of patients. Membranoproliferative glomerulonephritis (GN) was the second most common cause found in 21%. Patients with AA-amyloidosis were more likely to be HIV infected (67 vs.17%; p=0.036) and tended to have a higher rate of repeated systemic infections (92 vs. 50%; p=0.069). Patients with AA-amyloidosis presented with progressive renal disease and nephrotic-range proteinuria but most patients had no peripheral edema or systemic hypertension. Development of proteinuria preceded the decline of GFR for approximately 1--2 years.
Conclusions: AA-amyloidosis was the predominant cause of progressive renal disease in the last 10 years in patients with IVDU. The highest rate of AA-amyloidosis observed was seen in HIV infected patients with IVDU. We speculate that chronic HIV-infection as well as the associated immunosuppression might promote development of AA-amyloidosis by increasing frequency and duration of infections acquired by IVDU.